Clinical Trial: Pregnenolone for Cannabis Use Disorder and Depression

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07685964) titled 'Pregnenolone for Cannabis Use Disorder and Depression' on June 29.

Brief Summary: This is UG3 phase of a multi-site, milestone-driven UG3/UH3 research program evaluating pregnenolone for individuals with co-occurring cannabis use disorder (CUD) and major depressive disorder (MDD). Pregnenolone is a neurosteroid that modulates cannabinoid receptor signaling and may reduce cannabis-related effects while also improving mood-related symptoms.

The primary objective of the UG3 phase is to establish feasibility and generate preliminary data to support a subsequent UH3 randomized clinical trial. Key preparatory activities include obtaining ...